Özde Nisa Türkkan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Özde Nisa Türkkan has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Nurdan Yıldız
Department of Pediatric Nephrology, Marmara University School of Medicine, Istanbul, Turkey
3 shared publications - Alev Yilmaz
Division of Pediatric Nephrology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
2 shared publications - Ayşe Seda Pınarbaşı
Department of Pediatric Nephrology Diyarbakır Children's Hospital Diyarbakır Turkey
2 shared publications - Bahriye Atmis
Department of Pediatric Nephrology, Faculty of Medicine, Cukurova University, Adana, Türkiye
2 shared publications - Ceren Alavanda
Department of Medical Genetics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
2 shared publications - Emre Leventoğlu
Department of Pediatric Nephrology, Konya City Hospital, Konya, Türkiye
2 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Awareness, perceptions, and practices regarding transition to adult care for nephropathic cystinosis in Türkiye: a nationwide cross-sectional survey of pediatric nephrologists
Background: Nephropathic cystinosis is a rare multisystem disorder in which transition from pediatric to adult care is particularly a vulnerable period because of lifelong treatment demands and the need for sustained multidisciplinary follow-up. We aimed to assess awareness, perceptions, and self-reported transition practices among pediatric nephrologists in Türkiye caring for patients with nephropathic cystinosis. Methods: We conducted a nationwide descriptive cross-sectional web-based survey of pediatric nephrologists in Türkiye who had longitudinally followed at least one patient with nephropathic cystinosis. A 59-item questionnaire covering awareness, perceptions, and self-reported practices was administered via Google Forms, and responses were analysed descriptively at the item level. Results: In this nationwide descriptive cross-sectional web-based survey, 48 pediatric nephrologists participated. Respondents worked mainly in university hospitals (47.9%) and training and research hospitals (39.6%) and had a median of 14 years of pediatric nephrology experience (IQR 6–17). Although 66.7% distinguished transition from transfer, familiarity with cystinosis-specific transition models was limited; only 16.7% had ever applied a structured model and 8.3% reported a written transition plan in their center. The most frequently perceived challenges were treatment non-adherence (89.6%) and disruption of multidisciplinary follow-up (87.5%). Most respondents reported marked differences between pediatric and adult services, and the median recommended age for initiating transition planning was 17.5 years (IQR 17–18). Overall, 91.7% supported the development of a national transition model (58.3% considered it definitely necessary and 33.3% necessary but difficult to implement without external support). Conclusions: Among pediatric nephrologists in Türkiye, awareness of transition-related risks in nephropathic cystinosis was high, but structured transition practices were uncommon and initiation of transition planning was generally recommended at a later age than suggested by current guidance. These findings indicate an implementation gap and support the development of a feasible national transition framework that can be adapted to local resources.
- 26 August 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Open AccessAwareness, perceptions, and practices regarding transition to adult care for nephropathic cystinosis in Türkiye: a nationwide cross-sectional survey of pediatric nephrologists
Background: Nephropathic cystinosis is a rare multisystem disorder in which transition from pediatric to adult care is particularly a vulnerable period because of lifelong treatment demands and the need for sustained multidisciplinary follow-up. We aimed to assess awareness, perceptions, and self-reported transition practices among pediatric nephrologists in Türkiye caring for patients with nephropathic cystinosis. Methods: We conducted a nationwide descriptive cross-sectional web-based survey of pediatric nephrologists in Türkiye who had longitudinally followed at least one patient with nephropathic cystinosis. A 59-item questionnaire covering awareness, perceptions, and self-reported practices was administered via Google Forms, and responses were analysed descriptively at the item level. Results: In this nationwide descriptive cross-sectional web-based survey, 48 pediatric nephrologists participated. Respondents worked mainly in university hospitals (47.9%) and training and research hospitals (39.6%) and had a median of 14 years of pediatric nephrology experience (IQR 6–17). Although 66.7% distinguished transition from transfer, familiarity with cystinosis-specific transition models was limited; only 16.7% had ever applied a structured model and 8.3% reported a written transition plan in their center. The most frequently perceived challenges were treatment non-adherence (89.6%) and disruption of multidisciplinary follow-up (87.5%). Most respondents reported marked differences between pediatric and adult services, and the median recommended age for initiating transition planning was 17.5 years (IQR 17–18). Overall, 91.7% supported the development of a national transition model (58.3% considered it definitely necessary and 33.3% necessary but difficult to implement without external support). Conclusions: Among pediatric nephrologists in Türkiye, awareness of transition-related risks in nephropathic cystinosis was high, but structured transition practices were uncommon and initiation of transition planning was generally recommended at a later age than suggested by current guidance. These findings indicate an implementation gap and support the development of a feasible national transition framework that can be adapted to local resources.
- Open Access
- 4 March 2026
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (7) , 2089-2097
Clinical course of proteinuria due to cubilin variants: a large multicenter pediatric cohort
Introduction: We aimed to evaluate the clinical and genetic characteristics and clinical course of children with persistent proteinuria associated with CUBN variants. Methods: Forty-eight children with CUBN variants from 15 pediatric nephrology centers were included. Patients’ characteristics, serum creatinine, albumin, hemoglobin, vitamin B12 levels, urinalysis, spot urine protein/creatinine (uPCR), microalbumin/creatinine (uACR), beta-2 microglobulin/creatinine (uBMCR) ratios, estimated glomerular filtration rates (eGFRs), treatments, kidney biopsies, and genetic findings were evaluated. Results: All patients had normal serum albumin and creatinine and preserved eGFR. There was no significant change in eGFR between the first and last visits ( p = 0.15), whereas uPCR was lower at the last visit ( p = 0.001). Kidney biopsy was performed in 13 (27%); light microscopy was normal in all except one patient with focal segmental glomerulosclerosis (FSGS). Thirty-five patients (72.9%) had ACEi/ARB therapy, which was discontinued in 21 patients without subsequent worsening of proteinuria. Overall, 26 distinct CUBN variants were identified, predominantly in the C-terminal region. The most frequent variant was c.10102A > G (p.Met3368Val). Variant types included 15 (57.7%) missense, 7 (27%) nonsense, 3 (11.5%) splicing, and 1 (3.8%) frameshift variants. Conclusions: In this multicenter, large pediatric cohort, proteinuria associated with CUBN variants generally followed a benign course over short to mid-term follow-up even without sustained ACEi/ARB therapy. Embedding targeted CUBN testing into the evaluation of children with asymptomatic proteinuria and normal kidney function may reduce unnecessary kidney biopsies and prolonged medication, while improving family counseling. We outline a stepwise care pathway → early genetic screening → conservative monitoring with periodic eGFR and proteinuria assessment → consideration of ACEi/ARB discontinuation and recommend prospective validation and cost-effectiveness studies.
- 4 March 2026
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (7) , 2089-2097
Open AccessClinical course of proteinuria due to cubilin variants: a large multicenter pediatric cohort
Introduction: We aimed to evaluate the clinical and genetic characteristics and clinical course of children with persistent proteinuria associated with CUBN variants. Methods: Forty-eight children with CUBN variants from 15 pediatric nephrology centers were included. Patients’ characteristics, serum creatinine, albumin, hemoglobin, vitamin B12 levels, urinalysis, spot urine protein/creatinine (uPCR), microalbumin/creatinine (uACR), beta-2 microglobulin/creatinine (uBMCR) ratios, estimated glomerular filtration rates (eGFRs), treatments, kidney biopsies, and genetic findings were evaluated. Results: All patients had normal serum albumin and creatinine and preserved eGFR. There was no significant change in eGFR between the first and last visits ( p = 0.15), whereas uPCR was lower at the last visit ( p = 0.001). Kidney biopsy was performed in 13 (27%); light microscopy was normal in all except one patient with focal segmental glomerulosclerosis (FSGS). Thirty-five patients (72.9%) had ACEi/ARB therapy, which was discontinued in 21 patients without subsequent worsening of proteinuria. Overall, 26 distinct CUBN variants were identified, predominantly in the C-terminal region. The most frequent variant was c.10102A > G (p.Met3368Val). Variant types included 15 (57.7%) missense, 7 (27%) nonsense, 3 (11.5%) splicing, and 1 (3.8%) frameshift variants. Conclusions: In this multicenter, large pediatric cohort, proteinuria associated with CUBN variants generally followed a benign course over short to mid-term follow-up even without sustained ACEi/ARB therapy. Embedding targeted CUBN testing into the evaluation of children with asymptomatic proteinuria and normal kidney function may reduce unnecessary kidney biopsies and prolonged medication, while improving family counseling. We outline a stepwise care pathway → early genetic screening → conservative monitoring with periodic eGFR and proteinuria assessment → consideration of ACEi/ARB discontinuation and recommend prospective validation and cost-effectiveness studies.
- 20 December 2025
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (3) , 446-457
Predictors of kidney survival in children with autosomal recessive polycystic kidney disease
Background The phenotype of autosomal recessive polycystic kidney disease (ARPKD) can be quite variable: some patients progress to end-stage kidney disease (ESKD) in infancy, while others may not require kidney replacement therapy (KRT) until later childhood or adolescence. This study aimed to evaluate clinical, biochemical, imaging, and genetic findings that may influence kidney prognosis in pediatric patients with ARPKD. Methods The patients diagnosed before birth or in the first month were classified as perinatal presenters and later than 1 month as non-perinatal presenters. Additionally, groups were formed based on estimated glomerular filtration rate (eGFR) at the last visit and variant types. Results Seventeen patients (8 male, 9 female) were enrolled in the study. Kidney survival rates at 5 years was 71.4% in the perinatal group, whereas it was 100% in the non-perinatal group. The early height-adjusted kidney dimension (haKD) was positively correlated with perinatal presentation and antenatal diagnosis. At the last follow-up, the mean eGFR was significantly lower in the truncating group with four patients (23.5%) progressing to stage-5 chronic kidney disease (CKD). Conclusions The kidney survival rate is lower in patients with early presentation. Initial low eGFR and severe variants are important predictors of kidney survival. Additionally, early high haKD may be associated with poor kidney outcome. Further studies with larger patient populations and long-term follow-up are necessary to better understand the prognosis of pediatric patients with ARPKD.
- 20 December 2025
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (3) , 446-457
Predictors of kidney survival in children with autosomal recessive polycystic kidney disease
Background The phenotype of autosomal recessive polycystic kidney disease (ARPKD) can be quite variable: some patients progress to end-stage kidney disease (ESKD) in infancy, while others may not require kidney replacement therapy (KRT) until later childhood or adolescence. This study aimed to evaluate clinical, biochemical, imaging, and genetic findings that may influence kidney prognosis in pediatric patients with ARPKD. Methods The patients diagnosed before birth or in the first month were classified as perinatal presenters and later than 1 month as non-perinatal presenters. Additionally, groups were formed based on estimated glomerular filtration rate (eGFR) at the last visit and variant types. Results Seventeen patients (8 male, 9 female) were enrolled in the study. Kidney survival rates at 5 years was 71.4% in the perinatal group, whereas it was 100% in the non-perinatal group. The early height-adjusted kidney dimension (haKD) was positively correlated with perinatal presentation and antenatal diagnosis. At the last follow-up, the mean eGFR was significantly lower in the truncating group with four patients (23.5%) progressing to stage-5 chronic kidney disease (CKD). Conclusions The kidney survival rate is lower in patients with early presentation. Initial low eGFR and severe variants are important predictors of kidney survival. Additionally, early high haKD may be associated with poor kidney outcome. Further studies with larger patient populations and long-term follow-up are necessary to better understand the prognosis of pediatric patients with ARPKD.
- Open Access
- 29 January 2025
- Published by Marmara University in Marmara Medical Journal
- Vol. 38 (1) , 29-35
Does cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improve survival in children with desmoplastic small round cell tumors? First experiences from Turkey
Objective: Desmoplastic small round cell tumor (DSRCT) is a rare form of highly aggressive sarcoma and despite multimodal therapy, mortality still remains high. The aim of the study is to review our experience in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in children with DSRCT. Patients and Methods: A retrospective review of patients with DSRCT followed in our institution between January 2020-January 2024 was performed. Demographics, radiological imaging, histopathology results, cytogenetic analyses, chemotherapy/radiotherapy protocols, operative data and outcomes were analyzed. Results: Three patients with DSRCT were identified. The median age was 13.3 years (12-16 years). HIPEC was performed after CRS in two patients, while HIPEC procedure could not be applied in one patient with unresectable tumor. One patient underwent reoperation/re-HIPEC for recurrence after seven months. One patient had the diagnosis after complete removal of the tumor. Patient required peritonectomy and HIPEC as a second operation due to peritoneal recurrence. The patients who underwent CRS and HIPEC are still alive for 33 and 34 months since initial diagnosis, nevertheless the patient who had an unresectable tumor died after 8 months. Conclusion: Cytoreductive surgery and HIPEC may be considered as a safe and feasible treatment option in children with DSRCT in experienced centers.
- 29 January 2025
- Published by Marmara University in Marmara Medical Journal
- Vol. 38 (1) , 29-35
Open AccessDoes cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improve survival in children with desmoplastic small round cell tumors? First experiences from Turkey
Objective: Desmoplastic small round cell tumor (DSRCT) is a rare form of highly aggressive sarcoma and despite multimodal therapy, mortality still remains high. The aim of the study is to review our experience in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in children with DSRCT. Patients and Methods: A retrospective review of patients with DSRCT followed in our institution between January 2020-January 2024 was performed. Demographics, radiological imaging, histopathology results, cytogenetic analyses, chemotherapy/radiotherapy protocols, operative data and outcomes were analyzed. Results: Three patients with DSRCT were identified. The median age was 13.3 years (12-16 years). HIPEC was performed after CRS in two patients, while HIPEC procedure could not be applied in one patient with unresectable tumor. One patient underwent reoperation/re-HIPEC for recurrence after seven months. One patient had the diagnosis after complete removal of the tumor. Patient required peritonectomy and HIPEC as a second operation due to peritoneal recurrence. The patients who underwent CRS and HIPEC are still alive for 33 and 34 months since initial diagnosis, nevertheless the patient who had an unresectable tumor died after 8 months. Conclusion: Cytoreductive surgery and HIPEC may be considered as a safe and feasible treatment option in children with DSRCT in experienced centers.
- Open Access
- 1 April 2023
- Published by Academician Publishing
Pediatri Polikliniklerinde Sık Görülen Vakalar
Ömrünü eğitime ve tıp bilimine adamış, pediatri alanında kendi eğitimini tamamlayan ve hala sürdüren yazarlarımız ile iki yıldır süren çalışmalarımızın meyvesi olan kitabımız için çok mutluyuz. Yedi yaşından beri gece gündüz demeden çalışan, pediatri uzmanlığını ve yan dalını hakkıyla tamamlamak için çok emek harcayan arkadaşlar, tecrübelerini ve öğrendiklerini eğitime yeni başlayan meslektaşlarına aktarmak için bir kılavuz olacak bu kitabı hazırladık. Bu kitabın; pratisyen hekim, pediatri asistanları ve uzmanlarına klinik pratikte en sık karşılaşacakları hastalıkların tanısı, kliniği ve tedavisi konusunda hızlıca bilgilere ulaşabilmeleri açısından çok büyük kolaylık sağlayacağına inanıyoruz. Bu nedenle acillerde, polikliniklerde ve servislerde sıkça başvurulan bir kitap olacağını düşünüyoruz.
- 1 April 2023
- Published by Academician Publishing
Open AccessPediatri Polikliniklerinde Sık Görülen Vakalar
Ömrünü eğitime ve tıp bilimine adamış, pediatri alanında kendi eğitimini tamamlayan ve hala sürdüren yazarlarımız ile iki yıldır süren çalışmalarımızın meyvesi olan kitabımız için çok mutluyuz. Yedi yaşından beri gece gündüz demeden çalışan, pediatri uzmanlığını ve yan dalını hakkıyla tamamlamak için çok emek harcayan arkadaşlar, tecrübelerini ve öğrendiklerini eğitime yeni başlayan meslektaşlarına aktarmak için bir kılavuz olacak bu kitabı hazırladık. Bu kitabın; pratisyen hekim, pediatri asistanları ve uzmanlarına klinik pratikte en sık karşılaşacakları hastalıkların tanısı, kliniği ve tedavisi konusunda hızlıca bilgilere ulaşabilmeleri açısından çok büyük kolaylık sağlayacağına inanıyoruz. Bu nedenle acillerde, polikliniklerde ve servislerde sıkça başvurulan bir kitap olacağını düşünüyoruz.
- Open Access
- 1 January 2023
- Published by Osmangazi Journal of Medicine in OSMANGAZİ JOURNAL OF MEDICINE
- Vol. 45 (5) , 747-754
Çocuklarda Hipertansiyon Risk Faktörü Olarak Obezite ve Metabolik Sendrom
Hipertansiyon (HT), çocuklarda giderek artan önemli bir sağlık sorunudur. Son 20 yıl içinde çevresel ve sosyal faktörlerdeki değişiklikler, daha az fiziksel aktivite, hızlı beslenme alışkanlıkları, obezite ve metabolik sendrom, HT gelişimini doğrudan etkilemektedir. Çalışmamızın amacı, 18 yıllık bir süreçte HT tanısıyla izlenen çocuklarda yıllar içinde obezite ve metabolik sendrom sıklığının artıp artmadığını belirlemektir. Ocak 2001-Aralık 2018 tarihleri arasında Çocuk Nefroloji Polikliniği’nde HT nedeni ile başvuran ve HT tanısı kesinleşen 377 hasta retrospektif olarak değerlendirildi. Hastalar, 2001-2009 döneminde başvuran hastalar (Grup I) ve 2010-2018 döneminde başvuran hastalar (Grup II) olmak üzere iki gruba ayrıldı ve iki grup obezite ve metabolik sendrom açısından karşılaştırıldı. Ortalama başvuru yaşı 11,4±4,5 yıldı. Hastaların %64’ü erkekti. Grup 2’deki hastaların yaş, VKİ, metabolik sendrom ve ailede hipertansiyon olma öyküsü Grup 1’den yüksekti. İki grup arasında obezite açısından fark yoktu (p>0,05). Çalışmamızın sonuçları, hipertansiyon tanısıyla izlediğimiz hastalarda son yıllarda 2009 ve öncesine göre hem VKİ’de hem de metabolik sendrom görülme oranında artış olduğunu göstermiştir. Bu değişiklikler, özellikle ergenlerde belirgindir. Çocuk ve ergenlerde sodyum alımının azaltılması ve yaşam tarzı değişikliği önerileriyle obezitenin önlenmesi, HT gelişiminin engellemesi ve tedavisinde ilk aşamayı oluşturur.
- 1 January 2023
- Published by Osmangazi Journal of Medicine in OSMANGAZİ JOURNAL OF MEDICINE
- Vol. 45 (5) , 747-754
Open AccessÇocuklarda Hipertansiyon Risk Faktörü Olarak Obezite ve Metabolik Sendrom
Hipertansiyon (HT), çocuklarda giderek artan önemli bir sağlık sorunudur. Son 20 yıl içinde çevresel ve sosyal faktörlerdeki değişiklikler, daha az fiziksel aktivite, hızlı beslenme alışkanlıkları, obezite ve metabolik sendrom, HT gelişimini doğrudan etkilemektedir. Çalışmamızın amacı, 18 yıllık bir süreçte HT tanısıyla izlenen çocuklarda yıllar içinde obezite ve metabolik sendrom sıklığının artıp artmadığını belirlemektir. Ocak 2001-Aralık 2018 tarihleri arasında Çocuk Nefroloji Polikliniği’nde HT nedeni ile başvuran ve HT tanısı kesinleşen 377 hasta retrospektif olarak değerlendirildi. Hastalar, 2001-2009 döneminde başvuran hastalar (Grup I) ve 2010-2018 döneminde başvuran hastalar (Grup II) olmak üzere iki gruba ayrıldı ve iki grup obezite ve metabolik sendrom açısından karşılaştırıldı. Ortalama başvuru yaşı 11,4±4,5 yıldı. Hastaların %64’ü erkekti. Grup 2’deki hastaların yaş, VKİ, metabolik sendrom ve ailede hipertansiyon olma öyküsü Grup 1’den yüksekti. İki grup arasında obezite açısından fark yoktu (p>0,05). Çalışmamızın sonuçları, hipertansiyon tanısıyla izlediğimiz hastalarda son yıllarda 2009 ve öncesine göre hem VKİ’de hem de metabolik sendrom görülme oranında artış olduğunu göstermiştir. Bu değişiklikler, özellikle ergenlerde belirgindir. Çocuk ve ergenlerde sodyum alımının azaltılması ve yaşam tarzı değişikliği önerileriyle obezitenin önlenmesi, HT gelişiminin engellemesi ve tedavisinde ilk aşamayı oluşturur.
- Open Access
- 30 August 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (4) , 1781-1790
Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study
Background/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to-treat nephrotic syndrome, considering the type of disease (steroid-sensitive or -resistant) and the dosing regimen. Materials and methods: This multicenter retrospective study enrolled children with difficult-to-treat nephrotic syndrome on rituximab treatment from 13 centers. The patients were classified based on low (single dose of 375 mg/m(2)) or high (2-4 doses of 375 mg/m(2)) initial dose of rituximab and the steroid response. Clinical outcomes were compared. Results: Data from 42 children [20 steroid-sensitive (frequent relapsing / steroid-dependent) and 22 steroid-resistant nephrotic syndrome, aged 1.9-17.3 years] were analyzed. Eleven patients with steroid-sensitive nephrotic syndrome (55%) had a relapse following initial rituximab therapy, with the mean time to first relapse of 8.4 +/- 5.2 months. Complete remission was achieved in 41% and 36% of steroid-resistant patients, with the median remission time of 3.65 months. At Year 2, eight patients in steroid-sensitive group (40%) and four in steroid-resistant group (18%) were drug-free. Total cumulative doses of rituximab were higher in steroid-resistant group (p = 001). Relapse rates and time to first relapse in steroid-sensitive group or remission rates in steroid-resistant group did not differ between the low and high initial dose groups. Conclusion: The current study reveals that rituximab therapy may provide a lower relapse rate and prolonged relapse-free survival in the steroid-sensitive group, increased remission rates in the steroid-resistant group, and a significant number of drug-free patients in both groups. The optimal regimen for initial treatment and maintenance needs to be determined.
- 30 August 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (4) , 1781-1790
Open AccessRituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study
Background/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to-treat nephrotic syndrome, considering the type of disease (steroid-sensitive or -resistant) and the dosing regimen. Materials and methods: This multicenter retrospective study enrolled children with difficult-to-treat nephrotic syndrome on rituximab treatment from 13 centers. The patients were classified based on low (single dose of 375 mg/m(2)) or high (2-4 doses of 375 mg/m(2)) initial dose of rituximab and the steroid response. Clinical outcomes were compared. Results: Data from 42 children [20 steroid-sensitive (frequent relapsing / steroid-dependent) and 22 steroid-resistant nephrotic syndrome, aged 1.9-17.3 years] were analyzed. Eleven patients with steroid-sensitive nephrotic syndrome (55%) had a relapse following initial rituximab therapy, with the mean time to first relapse of 8.4 +/- 5.2 months. Complete remission was achieved in 41% and 36% of steroid-resistant patients, with the median remission time of 3.65 months. At Year 2, eight patients in steroid-sensitive group (40%) and four in steroid-resistant group (18%) were drug-free. Total cumulative doses of rituximab were higher in steroid-resistant group (p = 001). Relapse rates and time to first relapse in steroid-sensitive group or remission rates in steroid-resistant group did not differ between the low and high initial dose groups. Conclusion: The current study reveals that rituximab therapy may provide a lower relapse rate and prolonged relapse-free survival in the steroid-sensitive group, increased remission rates in the steroid-resistant group, and a significant number of drug-free patients in both groups. The optimal regimen for initial treatment and maintenance needs to be determined.